secwatch / observer
8-K filed May 28, 2026, 4:45 PM ET ticker FOXO CIK 0001812360
M&A confidence high sentiment positive materiality 0.70

FOXO licenses epigenetics IP to founder's entity; 3% royalty capped at $1.3M, 40% equity option

FOXO TECHNOLOGIES INC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FOXO TECHNOLOGIES INC. entered into Strategic Technology License Agreement with Jon R. Sabes and LongevityFP Technologies, LLC valued at 3% of net revenues derived from commercialization of the Licensed IP, subject to an aggregate cap of (effective 2026-05-27).

Action
entry
Agreement
license
Counterparty
Jon R. Sabes and LongevityFP Technologies, LLC
Value
3% of net revenues derived from commercialization of the Licensed IP, subject to an aggregate cap of
Effective
2026-05-27
Exact text from the filing
On May 27, 2026, FOXO Technologies Inc. (the “ Company ”), together with its wholly-owned subsidiary, FOXO Labs, Inc. (“ FLI ”), entered into a Strategic Technology License Agreement (the “ Agreement ”) with Jon R. Sabes, the Company’s founder, and LongevityFP Technologies, LLC
View on SEC.gov

Browse all material agreements →

FOXO TECHNOLOGIES INC. filing history →

Source: SEC EDGAR
accession 0001493152-26-025636
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.